Cytokinetics, Inc. — 2016 Form 10-K Summary
Business context and reporting period
For the fiscal year ended December 31, 2016 (filed March 6, 2017). Cytokinetics is a clinical-stage biopharmaceutical company developing muscle activators; it had no products approved for sale and no commercial product revenue. Its lead programs were tirasemtiv for ALS, CK-2127107 for muscle-weakness conditions, and partnered omecamtiv mecarbil for heart failure.
Financial performance and liquidity
| Metric | 2016 | 2015 |
|---|---|---|
| Total revenue | $106.4 million | $28.7 million |
| Operating expenses | $87.7 million | $66.1 million |
| Operating income (loss) | $18.7 million | $(37.4) million |
| Net income (loss) | $16.5 million | $(37.5) million |
| Net cash from (used in) operations | $37.0 million | $4.9 million |
| Cash, cash equivalents and investments at year-end | $163.9 million | $111.6 million |
| Working capital at year-end | $125.4 million | $81.5 million |
| Total borrowings at year-end | $29.9 million | $14.6 million |
2016 operating margin was approximately 17.6%; this was not product-driven profitability, but primarily reflected collaboration license and milestone revenue. Revenue included $77.3 million from Astellas and $27.9 million from Amgen. The $50 million Astellas ALS license consideration and $26.7 million Amgen milestone were significant contributors. The filing reports no gross margin from product sales.
Fourth-quarter 2016 revenue was $33.1 million and net income was $7.2 million, compared with fourth-quarter 2015 revenue of $9.8 million and a net loss of $9.2 million. Operating cash flow was supported by partner payments and partly offset by ongoing R&D and administrative spending. The company reported a $518.3 million accumulated deficit.
Material changes versus prior year
- Revenue increased $77.7 million year over year, driving a return to reported annual net income after a $37.5 million loss in 2015. Revenue remains dependent on partner payments, reimbursements, licenses and milestones, rather than recurring product sales.
- R&D expense rose to $59.9 million from $46.4 million, mainly reflecting higher outsourced clinical costs, including VITALITY-ALS. General and administrative expense rose to $27.8 million from $19.7 million.
- Cash and investments grew by approximately $52.3 million, principally from Astellas and Amgen payments and debt proceeds. Borrowings increased, with $30 million gross principal outstanding at year-end.
Outlook, risks and unusual items
- Management expected 2017 R&D and G&A expenses to increase significantly; no specific numerical 2017 revenue or expense guidance is provided in the supplied filing text. It believed year-end resources would fund operations for at least 12 months, subject to assumptions and risks.
- VITALITY-ALS completed enrollment in 2016; results were pending. The filing highlights uncertainty over whether regulators would accept slow vital capacity as an adequate endpoint, and whether additional Phase 3 studies might be required. Earlier BENEFIT-ALS did not meet its primary ALSFRS-R endpoint, although it showed an SVC effect; tirasemtiv also had tolerability and discontinuation concerns.
- CK-2127107 was in Phase 2 development for SMA and COPD; Cytokinetics anticipated an ALS Phase 2 trial in mid-2017. Amgen began the Phase 3 GALACTIC-HF trial for omecamtiv mecarbil in December 2016. Partner control over development timing and continuation is a material dependency.
- The 2016 Astellas amendment added ALS development and granted Astellas an option on tirasemtiv. The company received $65 million in related upfront/accelerated payments; the separate $15 million tirasemtiv option fee was deferred at year-end. Potential milestones and royalties are contingent, not assured.
- In February 2017, after year-end, Cytokinetics agreed to sell RPI Finance Trust a 4.5% royalty on potential omecamtiv mecarbil sales for $90 million and to sell RPI $10 million of common stock. It also increased its planned Amgen Phase 3 co-investment to $40 million, in exchange for potential incremental royalties and co-promotion rights.
- A $4.5 million settlement with a CRO related to BENEFIT-ALS was recorded as a reduction of R&D expense in 2016. A clinical-trial expense control weakness led to a restatement of interim 2016 results; management said it was remediated by year-end, and the auditor reported effective internal control at December 31, 2016.
- Key risks include clinical and regulatory failure, reliance on Astellas and Amgen, future financing needs, debt covenants and repayment, competition, intellectual-property protection, and the absence of product revenue. The company reported no material legal proceedings remaining after the CRO settlement.
Important facts for investors to verify
- Review the full audited statements and notes for the timing and accounting of Astellas license revenue, partner reimbursements and milestone payments; 2016 earnings were substantially collaboration-dependent.
- Check subsequent clinical disclosures for VITALITY-ALS results, endpoint/regulatory feedback, and progress of CK-2127107 and GALACTIC-HF.
- Confirm liquidity after the February 2017 RPI transaction, the $40 million Amgen co-investment commitment, and scheduled debt service; the filing’s 12-month cash sufficiency assessment predates those subsequent events.
- Assess the potential dilution from equity issuance and outstanding warrants/options, and the terms and conditions attached to collaboration milestones, royalties and co-promotion rights.
- Verify continued effectiveness of the remediated clinical-accrual controls and monitor future financial reporting for revisions.